This article is more than 5 years old. Information may no longer be current.

Ellex receives grant to conduct trial of laser for early treatment of AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ADELAIDE, Australia — Ellex Medical Lasers has been awarded a $540,000 Victorian government grant to carry out a clinical trial investigating the efficacy of its Ellex 2RT for treating age-related macular degeneration, the company announced.

The Ellex 2RT, which delivers a controlled nanosecond dose of laser energy into the eye, is being evaluated as a potential early treatment for AMD, the release said.

"In applying the laser therapy we hope to halt, or partially reverse, the progression of AMD before it threatens a patient's sight," Robyn H. Guymer, MBBS, PhD, FRANZCO, head of macular research at the Centre for Eye Research Australia (CERA), said in the release.

The trial, which will be conducted at the Royal Victorian Eye and Ear Hospital with the support of the CERA, will enroll 50 patients with early-stage AMD.

The grant was awarded as part of the $41 million Victoria's Science Agenda investment fund, the release said.